{"schema":"hottub-news/story/v1","story":"st_ahew5msuk6zer6gwzrja","title":"19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/19-3-weight-loss-at-week-48-phase-data-of-olatorepatide-hansohs-dual-ahew5msuk6","count":1,"items":[{"id":"n_ahew5msuk6zer6gwzrja","seq":1263666,"kind":"article","title":"19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD","url":"http://www.prnewswire.com/news-releases/19-3-weight-loss-at-week-48-phase--data-of-olatorepatide-hansohs-dualbiased-glp1gip-agonist-presented-at-easd-302896912.html","published":"2026-10-02T04:35:14Z","seen":"2026-10-02T04:35:14Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","science","health","business"],"authors":["Hansoh Pharma"],"entities":[{"id":"Q61523534","name":"chanoclavine-I dehydrogenase easD","type":"event"}],"story":"st_ahew5msuk6zer6gwzrja","category":"health","category_p":0.4399999976158142,"sentiment":"neutral","tone":-0.11999999731779099,"political":0.029999999329447746}]}